Tiziana Life Sciences LtdNASDAQ:TLSANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.9999
- TODAY'S CHANGE (%)0.0599 (6.3723%)
- Bid / Lots1.0000/ 6
- Ask / Lots1.0200/ 4
- Open / Previous Close0.9400 / 0.9400
- Day Range
- 52 Week Range
- Volume516,793
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLSA |
|---|---|---|
| 09:32 ET | 42170 | 0.94 |
| 09:34 ET | 334 | 0.94 |
| 09:41 ET | 5100 | 0.949799 |
| 09:43 ET | 5400 | 0.9498 |
| 09:45 ET | 44532 | 0.95 |
| 09:48 ET | 1000 | 0.95 |
| 09:56 ET | 2500 | 0.95 |
| 09:59 ET | 6634 | 0.94515 |
| 10:03 ET | 2000 | 0.95 |
| 10:06 ET | 1200 | 0.94999 |
| 10:08 ET | 4620 | 0.941804 |
| 10:10 ET | 1449 | 0.95 |
| 10:19 ET | 9981 | 0.96 |
| 10:21 ET | 1000 | 0.98 |
| 10:24 ET | 100 | 0.97 |
| 10:26 ET | 2175 | 0.98 |
| 10:32 ET | 300 | 0.97 |
| 10:33 ET | 100 | 0.97 |
| 10:42 ET | 2986 | 0.97 |
| 10:46 ET | 250 | 0.97 |
| 10:51 ET | 1500 | 0.9747 |
| 11:00 ET | 258 | 0.97 |
| 11:04 ET | 250 | 0.97 |
| 11:06 ET | 1055 | 0.971551 |
| 11:18 ET | 1526 | 0.97156 |
| 11:24 ET | 125 | 0.97 |
| 11:26 ET | 100 | 0.9716 |
| 11:36 ET | 1300 | 0.97 |
| 11:40 ET | 204 | 0.97 |
| 11:58 ET | 475 | 0.971351 |
| 12:03 ET | 797 | 0.97 |
| 12:07 ET | 5305 | 0.9716 |
| 12:09 ET | 15744 | 0.98 |
| 12:12 ET | 4509 | 0.99 |
| 12:23 ET | 203 | 0.9902 |
| 12:32 ET | 3752 | 1 |
| 12:34 ET | 49529 | 1 |
| 12:36 ET | 73653 | 1.01 |
| 12:38 ET | 9963 | 1.04 |
| 12:39 ET | 200 | 1.04 |
| 12:41 ET | 200 | 1.0241 |
| 12:45 ET | 11868 | 1.0305 |
| 12:50 ET | 3006 | 1.03 |
| 12:52 ET | 200 | 1.03 |
| 01:03 ET | 8984 | 1.01 |
| 01:06 ET | 6496 | 1.0197 |
| 01:08 ET | 172 | 1.04 |
| 01:26 ET | 5859 | 1.01 |
| 01:32 ET | 2188 | 1 |
| 01:33 ET | 355 | 1.01 |
| 01:46 ET | 290 | 1.01 |
| 01:51 ET | 5600 | 0.995 |
| 02:06 ET | 10000 | 0.995 |
| 02:09 ET | 10200 | 0.9901 |
| 02:11 ET | 750 | 0.9901 |
| 02:13 ET | 815 | 0.9931 |
| 02:15 ET | 1500 | 1 |
| 02:27 ET | 500 | 1.01 |
| 02:31 ET | 600 | 1.0056 |
| 02:40 ET | 5082 | 1 |
| 02:44 ET | 7800 | 0.99 |
| 02:47 ET | 12996 | 1 |
| 03:02 ET | 392 | 1.0099 |
| 03:03 ET | 2513 | 0.99 |
| 03:16 ET | 2000 | 0.9999 |
| 03:18 ET | 400 | 1 |
| 03:21 ET | 1000 | 1 |
| 03:23 ET | 1000 | 0.9997 |
| 03:25 ET | 272 | 0.995 |
| 03:30 ET | 200 | 1 |
| 03:32 ET | 500 | 0.9999 |
| 03:43 ET | 17413 | 1 |
| 03:45 ET | 700 | 0.9999 |
| 03:48 ET | 1300 | 0.9999 |
| 03:50 ET | 479 | 0.9999 |
| 03:52 ET | 2700 | 0.9998 |
| 03:54 ET | 5006 | 0.9999 |
| 03:56 ET | 1068 | 0.999 |
| 03:57 ET | 36579 | 1 |
| 03:59 ET | 3758 | 0.9999 |
May 30, 2024
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research, from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 13, 2024
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab, from 7:00AM ET on Monday May 13, 2024 by Dow Jones
7:00AM ET on Monday May 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tiziana Life Sciences Ltd | 103.1M | -6.7x | --- |
Maia Biotechnology Inc | 103.7M | -3.0x | --- |
Athira Pharma Inc | 100.4M | -0.9x | --- |
Vistagen Therapeutics Inc | 104.3M | -1.1x | --- |
Verastem Inc | 100.3M | -0.9x | --- |
Eledon Pharmaceuticals Inc | 105.9M | -2.0x | --- |
Company Information
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Contact Information
- Headquarters
- 3Rd Floor, 11-12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
- Phone
- 207-495-2379
- Fax
- ---
Executives
- Executive Chairman of the Board
- Gabriele Cerrone
- Chief Executive Officer, Chief Scientific Officer, Executive Director
- Kunwar Shailubhai
- Finance Director
- Keeren Shah
- Senior Director, CMC and Non - Clinical Development
- Jules Jacob
- Chief Development Officer
- William Clementi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $103.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 103.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.47 |
EPS | $-0.15 |
Book Value | $0.19 |
P/E Ratio | -6.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
